Join our panel of industry leaders for this forward-looking discussion on the fascinating implications of the broad-reaching Inflation Reduction Act (IRA) on the home and alternate site infusion industry.
Relevant provisions in the IRA include:
- $2,000/year cap on patient out-of-pocket costs for Medicare Part D drugs, beginning in 2025
- Medicare can negotiate the price of prescription drugs with manufacturers, beginning with 10 drugs in 2026, expanding by 15 drugs in 2027 and 2028, and expanding again by 20 drugs in 2029--for a total of 60 drugs by 2029
- Pharmaceutical companies will be required to issue an “inflation rebate” for Medicare drugs whose prices they set higher than the rate of inflation. A similar provision for drugs covered under commercial insurance failed.
Panelists will include:
- Connie Sullivan, NHIA President and CEO
- Logan Davis, Vice President of Trade, Vital Care Inc
- Jayson Slotnick, Partner, Health Policy Strategies
- Jennifer Snow, Vice President of Market Economics, AmerisourceBergen
We will also provide a brief update on the status and timeline for the Preserving Patient Access to Home Infusion Act.